OncLive On AirTM is a podcast from OncLive® that provides oncology professionals with the resources and information they need to provide the best patient care. Segments cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. New episodes with exclusive interviews with leading oncology experts are released on Mondays and Thursdays.
August 26th 2021
Dr. Janjigian discusses the FDA approval of nivolumab plus chemotherapy in advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, key findings from the pivotal CheckMate-649 trial, and future directions with immunotherapy in the field.
August 23rd 2021
Dr. Krie and Dr. Yuan discussed treatment-related adverse effects one should be aware of and prepared to manage, recommended management strategies for these TRAEs, and important points to emphasize to patients before they begin treatment.
August 19th 2021
Dr. Labaki and Dr. Trinh discuss their research on the recovery of cancer screening tests, its link with potential racial disparities from the COVID-19 pandemic, and how the community can continue to emphasize the importance of cancer screening while working to close these disparities in cancer care.
August 16th 2021
Dr. Chachoua discusses key guidelines for lung cancer screening, the psychological and financial implications of screening, and the opportunities of a screening initiative instated by NYU Langone Health.
August 12th 2021
Drs. Brown and Kurzrock discuss the current and future applications of next-generation sequencing in breast cancer, the role of tissue-based testing in light of the growing role for liquid-based testing, and some of the emerging technologies that could overcome current barriers to biomarker testing.
August 9th 2021
Dr. Moreau discusses the FDA approval of isatuximab-irfc plus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma, key findings from the pivotal IKEMA trial, and future directions with the combination.
August 5th 2021
Dr. Weber discusses exciting research presented during the 2021 ASCO Annual Meeting in melanoma with combination and single-agent checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and more.
August 2nd 2021
Chevon M. Rariy, MD, discusses how the implementation of telehealth during the COVID-19 pandemic shed light on the need for increased access to care for patients with cancer, as well as the potential benefits in-home infusions could offer to patients receiving chemotherapy.
July 29th 2021
Dr. George and Dr. Hurley discuss the data generated from their study on the correlation between deleterious variants in genes and the development of hereditary breast and ovarian cancers in populations throughout the Caribbean.
July 28th 2021
Dr Mahtani and colleagues highlight key clinical trials such as DESTINY-Breast01, HER2CLIMB, NALA, and SOPHIA in the setting of advanced HER2-positive breast cancer and discuss the practical considerations of these data.
July 28th 2021
In the second segment, Dr Mahtani and colleagues discuss data from select clinical trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.
July 28th 2021
In the first segment, Dr Mahtani and colleagues outline challenges and remaining unmet needs in the management of patients with HER2-positive breast cancer.
July 26th 2021
Drs Brown and Husain discuss the current and future applications of next-generation sequencing in lung cancer, the role of tissue-based testing in light of the growing role for liquid-based testing, and some of the emerging technologies that could overcome current barriers to biomarker testing.
July 22nd 2021
Dr. Tagawa discusses the FDA approval of sacituzumab govitecan in urothelial cancer, key efficacy and safety data from the pivotal TROPHY-U-01 trial, and expectations for the confirmatory TROPiCS-04 trial.
July 19th 2021
Dr. Jabbour discusses the optimal use of ponatinib in chronic myeloid leukemia and data from the 2021 ASCO Annual Meeting with the combination of blinatumomab and ponatinib in Ph-positive acute lymphoblastic leukemia.
July 15th 2021
Dr. Mayer discusses the mechanism of action of SERDs in ER-positive breast cancer, highlighted data from the AMEERA-1 trial with amcenestrant and palbociclib, and details future research efforts with SERDs.
July 12th 2021
Dr. Wainberg discusses factors that help steer treatment selection in HER2-positive gastrointestinal malignancies, advances on the horizon, and more.
July 8th 2021
Dr. Rariy, Ms. Brown, and Ms. Greenman discuss how the COVID-19 pandemic has led to a significant delay in cancer diagnoses, impacted the training of oncologists, and revolutionized telehealth.
July 5th 2021
Dr. O’Malley discusses key findings from 6 trials that were presented at the virtual 2021 SGO Annual Meeting on Women’s Cancer.